/

IONS

Ionis Pharmaceuticals, Inc.Pre-market

43.67−1.61 −3.56%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delayPre-market 44.05 +0.87%

Open

45.46

Prev close

45.28

Day range

43.6445.46

52-week range

42.6386.74

Volume

1.95M0.58×

Mkt cap

7.26B

P/E ttm

—

Fwd P/E

-39.26

EPS ttm

-3.48

Div yield

0.00%

Earnings

Jul 29, 2026

From 52w high

−49.65%

Price Chart

Yahoo Finance · delayed

IONSOct 12, 2026O 45.37H 45.46L 43.62C 43.67−1.61 (−3.56%)Vol 1.95M

SMA 5052.65
SMA 20069.34

1Y change −37.59% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IONS Ionis Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.39%
1 month: −19.44%
3 months: −23.05%
6 months: −41.73%
Year to date: −44.80%
1 year: −37.59%

Valuation & ownership

Market cap: 7.26B
Enterprise value: 7.34B
P/E (ttm): —
Forward P/E: -39.26
PEG ratio: 27.33
Price / book: 16.45
Price / sales (ttm): 8.30
EV / EBITDA: -12.67
EPS (ttm): -3.48
EPS (forward): -1.11
Beta (5y monthly): 0.38
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 166.18M
Float: 164.82M
Short % of float: 17.94%
Short ratio (days): 5.07
Held by insiders: 0.61%
Held by institutions: 110.34%
Avg volume (3m): 3.36M
50-day average: 52.65
200-day average: 69.34
52-week change: −37.59%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 36.3
vs 50-day SMA: −17.05%
vs 200-day SMA: −37.02%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.41%
Realised vol (20d, ann.): 52.5%
From 52-week high: −49.65%
From 52-week low: +2.44%

ANR

Analyst Consensus

22 analysts

Consensus

Buy

1.79 on a 1 (strong buy) – 5 (sell) scale

Mean target

83.64

+91.52% implied

Low 54.00Median 85.00High 105.00

Recommendation trend

Now19 / 5 / 0
1m ago / 5 /

DES

About Ionis Pharmaceuticals, Inc.

Yahoo Finance profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 1,480

SEAS

Seasonality · IONS

2007–2026 · monthly returns

Strongest month Jun +6.50%Weakest month Feb −2.73%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.5	-1.8	-7.5	-0.4	2.3	3.6	-34.7	16.6	-26.0	-2.2			−44.8%
2025	-8.8	4.0	-9.1	1.8	9.1	17.9	8.8	-0.8	53.4	13.6	11.3	-4.4	+126.3%
2024	1.6	-12.0	-4.1	-4.8	-8.9	26.9	3.8	-3.6	-16.0	-4.2	-6.9	-2.2	−30.9%
2023	5.6	-10.0	-0.4	-1.0	15.6	0.3	1.0	-2.8	12.6	-2.4	11.7	2.3	+33.9%
2022	4.5	5.0	11.0	-0.8	-0.7	1.4	1.5	13.2	4.0	-0.1	-7.7	-7.4	+24.1%
2021	6.2	-12.8	-14.2	-4.8	-13.0	7.1	-6.9	7.1	-15.6	-5.0	-16.8	14.8	−46.2%
2020	-3.5	-12.9	-6.9	17.4	1.2	4.9	-2.4	-5.3	-12.9	-1.1	7.6	11.9	−6.4%
2019	7.3	22.4	14.3	-8.4	-11.7	-2.0	2.5	-4.0	-5.2	-7.0	14.8	-5.6	+11.7%
2018	4.4	0.6	-16.5	-2.4	8.4	-10.7	4.8	4.6	12.9	-3.9	17.6	-7.3	+7.5%
2017	-7.0	11.8	-19.2	19.9	-5.0	11.1	3.0	2.3	-5.4	12.6	-2.8	-9.4	+5.2%
2016	-37.1	-11.2	17.2	1.2	-44.6	2.6	25.3	1.6	23.6	-29.1	68.4	9.3	−22.8%
2015	11.0	0.1	-7.1	-10.9	18.7	-14.5	-4.6	-8.6	-19.4	19.1	26.8	1.5	+0.3%
2014	28.2	-0.1	-15.3	-38.4	9.8	17.9	-10.0	31.5	-4.7	18.6	12.4	19.2	+55.0%
2013	39.2	1.2	15.2	32.2	-3.1	23.9	7.4	-10.5	45.3	-11.4	16.5	2.8	+281.6%
2012	13.2	11.6	-3.7	-8.8	23.6	21.3	1.0	12.3	3.4	-38.6	6.5	13.5	+44.8%
2011	-10.1	0.2	-0.9	3.8	-1.6	-0.8	-5.7	-13.3	-9.5	22.3	-10.5	-2.8	−28.8%
2010	0.5	-20.8	23.6	-1.6	-14.5	4.0	3.3	-21.0	7.6	8.8	3.3	7.2	−8.9%
2009	-0.4	-9.0	16.7	4.5	-12.0	19.6	10.8	-11.7	-9.7	-13.0	-15.5	3.7	−21.7%
2008	-1.0	-7.7	-2.0	-16.5	20.0	-3.6	25.7	3.2	-4.5	-16.8	-18.4	23.6	−10.0%
2007	-6.6	-12.2	1.6	10.4	-1.7	-3.8	7.5	18.5	21.3	17.7	0.4	-11.0	+41.6%

INSD

Insider Activity · IONS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

363.1K shares

Sells, 6 months

360.4K shares

Net shares

+2.7K

Net change in insider shares

+0.30%

Date	Insider	Transaction	Shares	Value
Jul 30, 2026	Hayden Michael ReubenDirector	Purchase at price 51.60 - 53.38 per share.	20K	$1.06M
Jul 14, 2026	Herman Joan EDirector	—	5.2K	—
Jul 14, 2026	Berthelsen Spencer RDirector	—	5.2K	—
Jul 6, 2026	Diaz Allene M.Director	Sale at price 85.42 per share.	10.1K	$863.64K
Jul 6, 2026	Diaz Allene M.Director	Conversion of Exercise of derivative security at price 47.11 per share.	10.1K	$476.33K
Jul 6, 2026	Kordasiewicz Holly BOfficer	Sale at price 84.30 per share.	362	$30.52K
Jul 6, 2026	Bennett C FrankOfficer	Sale at price 83.58 - 85.46 per share.	20.5K	$1.74M
Jun 30, 2026	Klein Joseph S IiiDirector	Sale at price 79.04 - 79.45 per share.	11.5K	$910.42K
Jun 30, 2026	Klein Joseph S IiiDirector	Conversion of Exercise of derivative security at price 39.94 per share.	11.5K	$460.03K
Jun 25, 2026	O'Neil Patrick RGeneral Counsel	Sale at price 80.00 per share.	3.1K	$245.52K
Jun 25, 2026	Baroldi JosephOfficer	Sale at price 80.16 per share.	5.6K	$451.70K
Jun 25, 2026	Baroldi JosephOfficer	Conversion of Exercise of derivative security at price 32.60 - 56.78 per share.	5.6K	$277.18K
Jun 25, 2026	Schneider EugeneOfficer	Sale at price 81.05 per share.	26K	$2.11M
Jun 25, 2026	Schneider EugeneOfficer	Conversion of Exercise of derivative security at price 60.89 per share.	26K	$1.58M
Jun 25, 2026	Monia Brett PChief Executive Officer	Sale at price 78.41 - 80.59 per share.	85.6K	$6.83M
Jun 25, 2026	Monia Brett PChief Executive Officer	Conversion of Exercise of derivative security at price 32.60 - 56.78 per share.	85.6K	$4.00M
Jun 24, 2026	Swayze Eric EOfficer	Sale at price 79.18 per share.	10.6K	$839.49K
Jun 14, 2026	Berthelsen Spencer RDirector	Sale at price 73.49 per share.	8K	$587.92K
Jun 14, 2026	Berthelsen Spencer RDirector	Conversion of Exercise of derivative security at price 24.42 per share.	8K	$195.36K
Jun 11, 2026	Kordasiewicz Holly BOfficer	Sale at price 73.09 - 74.05 per share.	60.8K	$4.47M

13F

Investors Holding IONS

latest 13F filings of 29 followed managers

Investors holding IONS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$44.4M	0.06%	559.41K	+83%	Q2 2026
ARK Investment Management · Cathie Wood	$23.8M	0.15%	300.77K	+4.2%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IONS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IONS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ionis Pharmaceuticals, Inc.

Seasonality · IONS

Insider Activity · IONS

Congress Trades · IONS

Investors Holding IONS

Investors Holding IONS

Congress Trades · IONS

Insider Activity · IONS

Seasonality · IONS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ionis Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News